Hospital
Christus Santa Rosa Health Care Corporation
Christus Santa Rosa Health Care Corporation was paid $69.09M by Medicaid between Aug 2019 and Dec 2024, across 218 billing codes. Its largest line is 99284, emergency room visit (serious) — 31% of everything it billed.
33Billing provider infoCHRISTUS SANTA ROSA HEALTH CARE CORPORATION
SAN ANTONIO, TX 78207
SAN ANTONIO, TX 78207
33aNPI1821004151assigned 07/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$69.09M
24GClaims740,025
24DCodes billed218
24AFirst – last monthAug 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#1 of 109
Median peer was paid$1.15M
This provider vs. median60×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 282 | $11K | |
| 2020 | 21,928 | $1.23M | |
| 2021 | 171,893 | $12.64M | |
| 2022 | 228,593 | $19.08M | |
| 2023 | 202,047 | $24.22M | |
| 2024incomplete | 115,282 | $11.90M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 30,445 | 29,437 | $21.64M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 165,319 | 162,146 | $8.57M |
| G0378 | Hospital observation service, per hour | 12% | 2,598 | 2,490 | $8.13M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4.7% | 4,375 | 4,307 | $3.23M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.9% | 102,964 | 95,415 | $2.70M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 3.6% | 12,552 | 11,359 | $2.46M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 3.1% | 664 | 639 | $2.17M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 2.8% | 5,314 | 5,170 | $1.95M |
| 76819 | Fetal biophysical profile; without non-stress testing | 2.5% | 11,900 | 8,410 | $1.73M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.0% | 31,058 | 28,758 | $1.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 23,830 | 23,415 | $1.24M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.5% | 5,354 | 4,992 | $1.06M |
206 more codes
| 92587 | 1.5% | 4,749 | $1.06M | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.3% | 33,062 | $888K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 11,561 | $727K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,217 | $541K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 17,541 | $522K |
| 92579 | <1% | 3,603 | $499K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,347 | $496K |
| 92567 | <1% | 7,950 | $440K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 7,306 | $398K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,956 | $393K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 562 | $375K |
| 95813 | <1% | 495 | $339K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 942 | $319K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 5,307 | $314K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,193 | $261K |
| 94010 | <1% | 1,525 | $260K | |
| 87428 | <1% | 4,233 | $246K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,850 | $241K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,926 | $175K |
| 72082 | <1% | 1,740 | $171K | |
| 76818 | <1% | 795 | $171K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,861 | $167K |
| 80053 | Comprehensive metabolic panel | <1% | 11,239 | $164K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 66 | $141K |
| D0120 | Dental checkup, returning patient | <1% | 4,943 | $129K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,577 | $126K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,268 | $122K |
| 76770 | <1% | 740 | $121K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,829 | $120K |
| D1120 | Dental cleaning, child | <1% | 3,517 | $113K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 715 | $113K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 7,003 | $111K |
| 95012 | <1% | 1,790 | $108K | |
| 74019 | <1% | 1,451 | $97K | |
| 76820 | <1% | 1,116 | $96K | |
| 76825 | <1% | 176 | $91K | |
| 86141 | <1% | 4,498 | $86K | |
| 87420 | <1% | 3,129 | $84K | |
| 99285 | Emergency room visit (most serious) | <1% | 238 | $74K |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 5,387 | $71K |
| 81001 | <1% | 14,748 | $71K | |
| 86317 | <1% | 583 | $67K | |
| 87081 | <1% | 6,138 | $66K | |
| 0240U | <1% | 6,576 | $61K | |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 490 | $60K |
| 74018 | <1% | 1,102 | $59K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,646 | $58K |
| 69210 | <1% | 178 | $55K | |
| 73100 | <1% | 839 | $53K | |
| 94060 | <1% | 119 | $51K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,118 | $51K |
| D1110 | Prophylaxis - adult | <1% | 1,029 | $50K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,283 | $48K |
| 95782 | <1% | 28 | $44K | |
| 29075 | <1% | 262 | $42K | |
| 85027 | <1% | 3,450 | $31K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 103 | $31K |
| 93325 | <1% | 175 | $30K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 684 | $29K |
| 84439 | <1% | 2,237 | $29K | |
| 72170 | <1% | 675 | $28K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 143 | $26K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 535 | $26K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 67 | $26K |
| 67311 | <1% | 14 | $25K | |
| 86003 | <1% | 311 | $24K | |
| 76827 | <1% | 175 | $24K | |
| 97802 | <1% | 602 | $22K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 6,460 | $22K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 13 | $19K |
| 77073 | <1% | 267 | $18K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 1,738 | $18K |
| D0272 | Bitewings - two radiographic images | <1% | 860 | $17K |
| 85007 | <1% | 3,162 | $16K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 54 | $16K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,234 | $16K |
| D1351 | Sealant - per tooth | <1% | 651 | $15K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 150 | $15K |
| 94644 | <1% | 110 | $15K | |
| 72081 | <1% | 303 | $15K | |
| D8670 | Periodic orthodontic treatment visit | <1% | 244 | $15K |
| 82784 | <1% | 806 | $15K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 27 | $14K |
| 80069 | <1% | 1,187 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 342 | $13K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 59 | $12K |
| 85652 | <1% | 3,204 | $12K | |
| 83735 | <1% | 1,307 | $11K | |
| 0002A | <1% | 572 | $11K | |
| 0001A | <1% | 664 | $11K | |
| 92555 | <1% | 169 | $10K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,425 | $10K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 70 | $10K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 230 | $10K |
| 73560 | <1% | 160 | $10K | |
| 64642 | <1% | 59 | $9K | |
| 82728 | <1% | 433 | $9K | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 381 | $9K |
| 82787 | <1% | 564 | $9K | |
| 31720 | <1% | 96 | $9K | |
| 82785 | <1% | 376 | $8K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,394 | $8K |
| D0274 | Bitewings - four radiographic images | <1% | 293 | $8K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 93 | $8K |
| 78264 | <1% | 14 | $8K | |
| 86160 | <1% | 436 | $8K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 241 | $7K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 800 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,619 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 183 | $7K |
| 0072A | <1% | 156 | $7K | |
| 86225 | <1% | 315 | $6K | |
| 77072 | <1% | 131 | $6K | |
| 92557 | <1% | 44 | $6K | |
| 83516 | <1% | 519 | $6K | |
| 29065 | <1% | 14 | $6K | |
| 78262 | <1% | 14 | $5K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 320 | $5K |
| 92552 | <1% | 48 | $5K | |
| 93225 | <1% | 27 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 213 | $4K |
| D0330 | Panoramic radiographic image | <1% | 125 | $4K |
| 84999 | <1% | 44 | $4K | |
| 73140 | <1% | 46 | $4K | |
| 84305 | <1% | 130 | $4K | |
| 83993 | <1% | 115 | $4K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,149 | $4K |
| 81025 | <1% | 258 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 836 | $3K |
| 83690 | <1% | 301 | $3K | |
| 80076 | <1% | 252 | $3K | |
| 82977 | <1% | 311 | $3K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 38 | $3K |
| 80061 | Lipid panel | <1% | 163 | $3K |
| 86364 | <1% | 149 | $3K | |
| 80180 | <1% | 94 | $3K | |
| 99201 | <1% | 137 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 966 | $3K |
| 80320 | <1% | 145 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 29 | $3K |
| 0071A | <1% | 66 | $3K | |
| 82570 | <1% | 366 | $3K | |
| 73070 | <1% | 35 | $2K | |
| 86235 | <1% | 49 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 64 | $2K |
| D0160 | <1% | 165 | $2K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 289 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $2K |
| 92556 | <1% | 27 | $2K | |
| 85045 | <1% | 279 | $2K | |
| 92582 | <1% | 27 | $2K | |
| 84156 | <1% | 305 | $2K | |
| 92583 | <1% | 43 | $1K | |
| 92504 | <1% | 50 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 225 | $1K |
| 82610 | <1% | 80 | $1K | |
| 36591 | <1% | 38 | $1K | |
| 87040 | <1% | 88 | $1K | |
| 73090 | <1% | 31 | $1K | |
| 86480 | <1% | 19 | $1K | |
| 81002 | <1% | 290 | $1K | |
| 73080 | <1% | 16 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 13 | $988.72 |
| 73562 | <1% | 14 | $987.22 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 57 | $979.34 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 745 | $961.15 |
| 83550 | <1% | 70 | $952.76 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 93 | $938.73 |
| 83615 | <1% | 83 | $907.07 | |
| 86200 | <1% | 53 | $807.60 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 24 | $737.63 |
| 83540 | <1% | 70 | $722.38 | |
| 90686 | <1% | 2,325 | $643.03 | |
| 0081A | <1% | 30 | $599.23 | |
| 81003 | <1% | 169 | $548.02 | |
| 88304 | <1% | 87 | $533.56 | |
| 83520 | <1% | 14 | $418.18 | |
| D0170 | <1% | 30 | $358.93 | |
| 86039 | <1% | 27 | $354.67 | |
| 84100 | <1% | 78 | $338.00 | |
| 87338 | <1% | 15 | $295.94 | |
| 86256 | <1% | 27 | $276.67 | |
| 86812 | <1% | 14 | $260.54 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 466 | $217.44 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 17 | $206.35 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 16 | $206.34 |
| 82550 | <1% | 14 | $201.07 | |
| 83525 | <1% | 14 | $182.62 | |
| D1354 | <1% | 45 | $175.50 | |
| 90474 | <1% | 37 | $49.76 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 36 | $48.55 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 18 | $42.92 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 30 | $40.86 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 34 | $38.91 |
| 36416 | <1% | 429 | $31.75 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 52 | $24.76 |
| 90670 | <1% | 190 | $20.06 | |
| 90680 | <1% | 25 | $0.13 | |
| D9986 | 0% | 45 | $0.00 | |
| D0603 | 0% | 5,364 | $0.00 | |
| D0602 | 0% | 755 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 47 | $0.00 |
| 90698 | 0% | 96 | $0.00 | |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 42 | $0.00 |
| 82962 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDASKEVICH, CRIS (CEO)
Parent organizationCHRISTUS SANTA ROSA HEALTH CARE CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Christus Santa Rosa Health Care Corporation | San Antonio, TX | $144K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.